Randomized Controlled Trial
Copyright ©The Author(s) 2021.
World J Clin Cases. Oct 6, 2021; 9(28): 8413-8424
Published online Oct 6, 2021. doi: 10.12998/wjcc.v9.i28.8413
Table 1 Baseline characteristics in the intervention group and the control group
Characteristics
Total, n = 158
IG, n = 80
CG, n = 78
t
z
x2
P value
Caregiver characteristics
Age (yr), mean ± SD 47.4 ± 8.447.7 ± 8.647.0 ± 8.30.5200.604
Gender, n (%)0.9330.334
Male44 (27.8)25 (31.3)19 (24.4)
Female114 (72.2)55 (68.8)59 (75.6)
Work status, n (%)0.1410.932
Full-time102 (64.6)51 (63.8)51 (65.4)
Part-time24 (15.2)13 (16.3)11 (14.1)
Unemployed32 (20.3)16 (20.0)16 (20.5)
Relationship, n (%)0.2380.888
Son or daughter45 (28.5)23 (28.8)22 (28.2)
Spouse62 (39.2)30 (37.5)32 (41.0)
Others51 (32.3)27 (33.8)24 (30.8)
Education duration (yr), mean (IQR)9.0 (6.0)9.0 (6.0)9.0 (6.5)-0.2510.802
Patient characteristics
Age (yr), mean ± SD59.2 ± 10.960.6 ± 10.757.7 ± 10.91.6690.097
Gender, n (%)0.0820.774
Male25 (15.8)12 (15.0)13 (16.7)
Female133 (84.2)68 (85.0)65 (83.3)
Comorbidity, n (%)0.1180.732
Yes28 (17.7)15 (18.8)13 (16.7)
No130 (82.3)65 (81.3)65 (83.3)
Drug therapy, n (%)0.0760.783
DMARDs + GC117 (74.1)60 (75.0)57 (73.1)
DMARDs + GC + biologics41 (26.0)20 (25.0)21 (26.9)
Disease duration (yr), mean (IQR)5.5 (6.0)5.0 (5.0)6.5 (4.3)-1.8160.069
CRP (mg/L), mean ± SD18.00 ± 5.5217.74 ± 5.6518.25 ± 5.41-0.5790.563
ESR (mm/h), mean ± SD35.49 ± 5.3335.61 ± 5.2935.36 ± 5.410.2980.766
TNF-α (pg /ml), mean ± SD43.47 ± 9.5843.93 ± 9.0442.99 ± 10.150.6180.537
CDAI, mean ± SD20.00 ± 7.6319.97 ± 7.2920.04 ± 8.01-0.0600.952
SDAI, mean ± SD38.00 ± 8.7037.71 ± 8.6738.29 ± 8.78-0.4200.675
DAS28, mean ± SD4.92 ± 1.304.94 ± 1.294.89 ± 1.330.2510.802
HAQ, mean (IQR)1.12 (0.99)1.21 (0.99)1.11 (0.99)-0.4420.659
SDS, mean ± SD57.87 ± 5.5157.31 ± 4.7758.45 ± 6.15-1.3000.196
SAS, mean ± SD53.82 ± 9.6854.43 ± 8.3453.21 ± 10.910.7910.430